(Q38189525)

30 August 2017

1 reference

title

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient (English)

1 reference

30 August 2017

Marcello Tonelli

2

0 references

Christoph Wanner

series ordinal

1

object named as

Christoph Wanner

1 reference

30 August 2017

author name string

Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

19 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

85

1 reference

30 August 2017

issue

6

1 reference

30 August 2017

page(s)

1303-1309

1 reference

Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Diabetes and coronary risk equivalency: what does it mean?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Association between LDL-C and risk of myocardial infarction in CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Hyperlipidemia in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Association between serum lipids and survival in hemodialysis patients and impact of race

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Monitoring cholesterol levels: measurement error or true change?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Lipid re-screening: what is the best measure and interval?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Lipoprotein metabolism in chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

The effects of pravastatin on hyperlipidemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.31

7 January 2021

Identifiers

DOI

10.1038/KI.2014.31

1 reference

Dimensions Publication ID

30 August 2017

1003366297

0 references

1 reference